CITIUS ONCOLOGY INC (CTOR) Stock Income Statement
USA - NASDAQ:CTOR - US17331Y1091 - Common Stock
2 USD
+0.18 (+9.89%)
1.99 USD
-0.01 (-0.5%)
| TTM (2025-6-30) | 2024 (2024-9-30) | 2023 (2023-9-30) | 2022 (2022-9-30) | ||||
|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Operating Expenses | 38.81M | 20.57M | 12.12M | 4.86M | |||
| Research and Development | 10.27M | 4.92M | 4.24M | 3.43M | |||
| Selling, General, and Administrative Expenses | 28.47M | 15.65M | 7.88M | 1.43M | |||
| Operating Income | -38.81M | -20.57M | -12.12M | -4.86M | |||
| Income Before Taxes | -39.97M | -20.57M | -12.12M | -4.86M | |||
| Income Tax | 1.37M | 576.00K | 576.00K | 576.00K | |||
| Net Income | -41.76M | -21.15M | -12.70M | -5.43M | |||
| Per Share Data | |||||||
| EPS Diluted Total Ops | -0.60 | -0.31 | -0.18 | -0.08 | |||
| Statistics | |||||||
All data in USD